Enantat 400 400mg/ml 10ml Vial by Dragon-Pharma

Usage

1. Confirm your specific weekly testosterone dose target based on bloodwork baseline (total T, free T, LH, FSH, oestradiol) — Enantat 400's high concentration means small volume changes produce meaningful dose shifts.
2. Draw your calculated volume through a large-gauge needle (18G) to manage the higher viscosity of a 400 mg/ml oil-based formulation, then swap to a smaller gauge (23–25G) for intramuscular injection to minimise tissue trauma.
3. Inject into a large muscle group — gluteus maximus, vastus lateralis, or deltoid — rotating sites across the dosing week to preserve tissue integrity at each androgen-receptor-dense injection depot.
4. Maintain a strict twice-weekly schedule (e.g. Tuesday/Friday) to sustain stable free-testosterone levels in the serum window where AR occupancy remains consistently elevated above endogenous baseline.
5. Log each injection date, volume, and site; cross-reference with mid-cycle bloodwork (week 4–6) to verify that serum testosterone is reaching the target range associated with your dose per AR-saturation pharmacokinetics.
6. At cycle end, document the date of your last injection and begin counting forward through the ester clearance period before initiating your PCT protocol — preserving androgen receptor sensitivity for the recovery phase.

Warnings

Frequently asked questions

How does testosterone enanthate bind to the androgen receptor at the molecular level?

Once esterases cleave the enanthate chain, free testosterone enters target cells and occupies the ligand-binding domain (LBD) of the androgen receptor with a low-nanomolar dissociation constant (Kd), triggering conformational change, receptor dimerisation, and nuclear translocation. This high-affinity binding initiates transcription of anabolic genes including myosin heavy-chain isoforms and IGF-1, as confirmed by ARE-reporter gene assays in human muscle cell lines.

Why does DHT bind the androgen receptor more strongly than testosterone, and does that matter for Enantat 400 users?

Dihydrotestosterone (DHT) binds AR with an RBA approximately three to five times higher than testosterone because its A-ring reduction eliminates the 4,5 double bond, producing a more geometrically complementary fit within the receptor's LBD. For Enantat 400 users, this means androgenic effects in high-5α-reductase tissues (scalp, prostate) are amplified relative to the parent compound's muscle-focused signalling — a clinically relevant distinction when calibrating dose and monitoring protocols.

What is the difference between the genomic and non-genomic androgen receptor pathways activated by testosterone?

The genomic pathway is the primary mechanism: ligand-bound AR dimerises, binds androgen response elements (AREs) on DNA, and drives transcription of hypertrophy-related genes — a process taking hours and responsible for sustained muscle protein synthesis. The non-genomic pathway involves membrane-associated AR and rapid PI3K/Akt activation, producing anti-catabolic effects within minutes of receptor engagement. Both pathways are fully engaged at post-injection serum levels achievable with Enantat 400's 400 mg/ml concentration.

What practical advantage does the 400mg/ml concentration offer compared to standard 250mg/ml testosterone enanthate vials?

At 400 mg/ml, reaching a 400 mg weekly dose requires only 1 ml of Enantat 400 versus 1.6 ml of a 250 mg/ml product — a 37.5% volume reduction per injection. This matters when stacking multiple oil-based compounds: lower total volume per injection site reduces tissue displacement, discomfort, and the risk of oil embolism associated with large-volume injections.

How should the 10ml multi-dose vial be stored and managed after first puncture to maintain sterility?

Store the unopened vial at 15–25 °C, away from direct light. After first puncture, use a fresh sterile needle for every draw to prevent microbial contamination of the remaining solution. Wipe the rubber septum with 70% isopropyl alcohol before each entry. Dragon-Pharma's LAL-assay and sterility-tested batches ensure the starting baseline is clean; maintaining aseptic technique on every subsequent draw preserves that standard for the vial's useful life. (2) angle_used

Manufacturer

Dragon-Pharma's customer support infrastructure is structured around the analytical traceability of every product it releases — and Enantat 400 is a direct expression of that commitment. When a buyer contacts Dragon-Pharma's support team with a batch-specific query, representatives can reference HPLC content records and LAL endotoxin reports tied to that lot number, giving product verification a factual basis rather than a marketing assertion. This documentation-first support model distinguishes Dragon-Pharma from suppliers who operate without audit-ready batch records. For Enantat 400 specifically — where the 400 mg/ml concentration represents the ceiling of testosterone enanthate density in this product category — having confirmable potency data on hand allows the support team to address dosing and concentration queries with precision. Dragon-Pharma's response channels are designed to handle technical questions from experienced users who expect data, not generic assurances.